STAT1 exists in phosphorylated (pSTAT1) and unphosphorylated (uSTAT1) forms each regulated by IFN-Ȗ. Although STAT1 is a key mediator of the IFN-Ȗ signaling pathway, an essential component of the host cancer immunosurveillance system, STAT1 is also overexpressed in certain human cancers where the functions of pSTAT1 and uSTAT1 are ill-defined. Using a murine model of soft tissue sarcoma (STS), we demonstrate that disruption of the IFN effector molecule IRF8 decreases pSTAT1 and increases uSTAT1 in STS cells, thereby increasing their metastatic potential. We determined that the IRF8 gene promoter was hypermethylated frequently in human STS.
Introduction
Signal transducer and activator of transcription 1 (STAT1) is a DNA-binding protein that mediates IFN-γ-dependent gene expression. IFN-γ is a pleiotropic cytokine produced by activated T lymphocytes and natural killer (NK) cells. The IFN-γ/STAT1 signaling pathway was originally identified to play an essential role in host defense against microbial and viral infections. Recent studies, however, revealed that the IFN-γ/STAT1 signaling pathway is also critically important in host suppression of tumor development (1) (2) (3) . Mice lacking the p53 tumor suppressor gene and STAT1 formed a wider spectrum of tumors compared with STAT1 wt mice lacking only p53 (4) . Furthermore, STAT1
-/-mice formed significantly more carcinogen-induced sarcomas than wt mice. Therefore, STAT1 was viewed as a tumor suppressor (1) . On the other hand, the IFN-γ/STAT1 signaling pathway is a major signaling pathway for modulating both pro-and antiinflammatory responses, and approximately 20% of human cancers are estimated to develop from chronic inflammation (5) . Indeed, it has recently been reported that chronic IFN-γ signaling leads to hyperactivation of STAT1 and chronic inflammation-mediated spontaneous colorectal cancer development (6) . In addition, STAT1 accumulation and hyperactivation have been observed in multiple types of cancers (3, (7) (8) (9) (10) . Therefore, the IFN-γ/STAT1 signaling pathway might be a double-edged sword that functions to either suppress or promote cancer development depending on the cellular context.
Binding of IFN-γ to its physiological receptor, the IFN-γR, induces oligomerization of receptors, followed by rapid activation of the receptor-associated JAKs by transphosphorylation. The activated JAKs phosphorylate the intracellular domain of the IFN-γR, which then serves as a docking site for STAT1. The cytoplasmic STAT1 (cSTAT1) exists primarily in an unphosphorylated state (uSTAT1). uSTAT1 is recruited to the phosphorylated IFN-γR and is then itself phosphorylated. The phosphorylated STAT1s (pSTAT1) form homodimers and translocate to the nucleus to regulate gene expression by binding to gamma activation site (GAS) elements (TTCN 2-4 G/TAAA) in the promoters of IFN-γ target genes. Therefore, pSTAT1 is the key mediator of the IFN-γ signaling pathway. In contrast, uSTAT1 predominately exists in the cytoplasm and is constitutively expressed in most cells. However, pSTAT1 also induces STAT1 expression to increase uSTAT1 accumulation in the cytoplasm. In response to IFN-γ, STAT1 is rapidly phosphorylated but only lasts a few hours, whereas uSTAT1, newly synthesized by pSTAT1-activated transcription, can persist for several days (11) .
The function of pSTAT1 in regulation of IFN-γ target genes is well-established. uSTAT1 was originally considered as the latent form of STAT1. However, it has since been demonstrated that uSTAT1, in the absence of IFN-γ stimulation, also functions as a transcription factor (12, 13) . These observations indicate that both pSTAT1 and uSTAT1 are transcription factors and may both be involved in the IFN-γ-mediated tumor suppression or promotion. However, the relative role of pSTAT1 and uSTAT1 in tumor development is not well-defined. In a previous study, we showed that disruption of IRF8 function resulted in a dramatic up-regulation of uSTAT1 in mouse soft tissue sarcoma cells (14) . Here, we examined cSTAT1/uSTAT1 and nuclear STAT1 (nSTAT1/pSTAT1) protein levels in 123 human STS specimens and observed that cSTAT1 level is inversely correlated with disease-specific survival, whereas pSTAT1 is positively correlated with disease-specific survival. Furthermore, we mechanistically demonstrated that uSTAT1 is a negative regulator of the Fas-mediated apoptosis pathway that suppresses FasL-induced CAN-12-1347 apoptosis at least partially through repressing Fas and Bad expression in sarcoma cells.
Our data thus suggest that uSTAT1 is a tumor promoter and pSTAT1 is a tumor suppressor in human STS.
Materials and Methods

Mice and cells. BALB/c (H-2 d
) mice were obtained from the National Cancer Institute (NCI, Frederick, MD). All mice were housed, maintained and studied in accordance with approved NIH and Georgia Health Sciences University guidelines for animal use and handling. CMS4 cell line has been characterized as previously described (15) .
Human STS tumor specimens. Human STS specimens were collected from surgical specimens at The University of Texas M. D. Anderson Cancer Center and formatted into a tissue microarray (TMA) as previous described (16) . Specifically, one hundred twentythree archived paraffin blocks from STS surgical specimens were utilized For TMA construction (Supplemental Table 1 ), H&E-stained sections were reviewed from each of these STS tumor blocks by a sarcoma pathologist (AJL) to define areas of homogeneous, viable tumor. Using an automated TMA apparatus (ATA-27, Beecher Instruments), 0.6 mm punch samples were obtained from donor AS blocks. The selected tissue cores were formatted into a standard 4.5 x 2 x 1 cm recipient block. Two tissue cores were taken for each case and one TMA block containing a total of 246 cores of STS tumor tissue was constructed. Sections (4 ȝm) were cut, and one standard H&E stained slide was examined to verify the presence of viable tumor. Immunohistochemistry. Immunohistochemical staining was performed at the Georgia Pathology Service using anti-STAT1 mAb (BD Biosciences). The specimens were blocked with normal serum (1.5%) and then incubated in primary antibody for 30 min, followed by rinsing and staining with appropriate anti-species biotinylated antibody (1:2,000) for another 30 min. Color was developed by incubation with 3,3ƍ-diaminobenzidine solution (Sigma), followed by rinsing and counterstaining with hematoxylin. Positive and negative controls were run in parallel. Labeling intensity was graded by 2 separate observers (AJL and GL) in both the cytoplasmic and nuclear compartments as none (=0), weak (=1), moderate (=2), or strong (=3); the percentage of positive tumor cells (distribution) was estimated from the 2 paired TMA samples for each case as previously described (16) . Anti-CD8 antibody was obtained from Dako and used to stain individual slides as previously described (17) .
Experimental lung metastasis mouse model. The experimental lung metastasis mouse model was carried out as previously described (18) .
Analysis of tumor-infiltrating T cells. CMS4 cells were injected into BALB/c mice i.v., and tumor-bearing lungs were digested with collagenase as previously described (18) . Chromatin immunoprecipitation (ChIP) assay. ChIP assays were carried out using anti-IRF8 antibody (Santa Cruz) as previously described (19) . The STAT1 promoter DNA was detected by PCR using mouse STAT1 promoter-specific primers (Supplemental Table 2 ). Western blot analysis. Western blotting analysis was performed essentially as previously described (19) . The blot was probed with pSTAT1-, STAT1-, Bcl-2-, Bcl-xL-, Bad-and Jak1-specific antibodies (BD biosciences). Anti-β-actin antibody was obtained from Sigma.
Immunoprecipitation
Statistical Analysis. All statistical analysis was performed using SAS 9.2 and statistical significance was assessed using an alpha level of 0.05. Patient demographic and clinical characteristics were summarized using medians or proportions as applicable. Survival was estimated using the Kaplan-Meier method with 95% confidence intervals, with disease-specific mortalit as an endpoint. The time to disease-related death was computed from the date of surgery at MD Anderson Cancer Center to the date when the event of death was recorded, or the event was censored at the date of last follow-up assessment in event-free patients. Kaplan-Meier curves were used to determine DSS time; Log-rank To determine whether the above observations can be extended to human STS specimens we utilized a clinically annotated STS TMA and stained it for STAT1. Ninetytwo of the STS tumors (75%) included in the TMA were high grade, the majority (80%) were classified as undifferentiated pleomorphic STS. Positive cytoplasmic (cSTAT1) and nuclear STAT1 (nSTAT1) immunostainings were observed in 116 (94.3%) and 94 (76.4%) tumors, respectively. Cytoplasmic levels were high in 29.3% (n=36) of evaluable tumor samples; high nuclear expression was observed in 15.3% (n=19) of STS tumors
Expression intensity of nSTAT1 level was found to be associated with a clear trend towards prolonged disease-specific survival (DSS), however it was not statistically significant; median DSS of STS patients with low nSTAT1 levels was 58 months and has not been reached in the cohort of patients expressing high nSTAT1 levels (p=0.08; Fig.   3A ). In contrast, our data demonstrated that high cSTAT1 expression levels were strongly associated with decreased rates of STS-specific survival; median DSS of patients with high cSTAT1 expression levels was 46 months and has not been reached in the low cSTAT1 group (p=0.03; Fig. 3B ). In addition, cSTAT1 level was found to be negatively correlation of nSTAT1 level in these STS specimens (p=0.015) with 66.7% of specimens with low cSTAT1 expression scored as high nSTAT1 vs. 92% of specimens with high cSTAT1 expression. In summary, these results imply that nSTAT1 may function as a tumor suppressor, whereas, cSTAT1 as a tumor promoter in STS. 
IRF8 promoter DNA is hypermethylated in human STS.
Because STAT1 expression is potentially regulated by IRF8 (Fig. 1) , and the IRF8 promoter DNA is frequently methylated in human cancer cells (20) (21) (22) , we next sought to determine the methylation status of the IRF8 promoter DNA in human STS cells.
Genomic DNA was isolated from 10 human STS specimens and the IRF8 promoter DNA methylation status was analyzed. MS-PCR analysis indicated that the IRF8 promoter DNA is hypermethylated in all 10 specimens examined (Fig. 3C) .
STAT1 confers sarcoma cell resistance to FasL-induced apoptosis
Acquisition of resistance to apoptosis, including Fas-mediated apoptosis, is often associated with tumor progression (23, 24) . The positive correlation between STAT1 level and increased tumor burden (Figs. 1-3 ) suggest that STAT1 might promote tumor development through regulating apoptosis in sarcoma cells. To test this hypothesis, we silenced uSTAT1 expression in CMS4 cells (Fig. 4A) and analyzed the tumor cell sensitivity to FasL-induced apoptosis. While CMS4 cells were not sensitive to FasLinduced apoptosis, silencing uSTAT1 dramatically increased tumor cell sensitivity to FasL-induced apoptosis in vitro (Fig. 4B ) (p<0.01).
uSTAT1 regulates Fas and Bad expression
It has been shown that uSTAT1 directly regulates the expression of several genes, including Bcl-xL, Bcl-2l1, ccnd1, cMyc and STAT3 in several types of cells (25) (26) (27) (28) (29) (Fig. 5A) . However, the expression levels of Bcl-2l1, ccnd1, cMyc and STAT3 were not changed in STAT1-silenced cells (Fig. 5A) , suggesting cell type-dependent regulation of gene expression by uSTAT1. Because STAT1 mediates sarcoma cell sensitivity to Fasmediated apoptosis (Fig. 4B) , we then examined the expression levels of genes with known function in the Fas-mediated apoptosis pathway. RT-PCR analysis revealed that the expression levels of Fas and Bad are up-regulated in STAT1-silenced sarcoma cells (Fig. 5B & C) . Consistent with increased Fas mRNA level, STAT1-silenced CMS4 cells also expressed higher level of cell surface Fas protein as compared to the control cells (Fig. 5B) . It is known that it is the ratio of expression levels of pro-and anti-apoptotic genes that determines the sensitivity of cells to apoptosis induction. The observation that silencing STAT1 increases Bcl-xL expression level and at the same time significantly increased the tumor cell sensitivity to Fas-mediated apoptosis suggest that Bcl-xL function is neutralized by increased pro-apoptotic protein. To test this hypothesis, we performed immunoprecipitation using Bcl-xL-and Bcl-2-specific mAbs and analyzed Bcl-xL-and Bcl-2-associated pro-apoptotic proteins. We detected that Bad is associated with Bcl-xL protein (Fgi. 5D). Therefore, Bcl-xL and Bad form a protein complex in the CMS4 tumor cells.
Tumor-infiltrating cytotoxic T lymphocytes express FasL.
Fas is a death receptor that by itself does not initiate apoptosis in tumor cells. FasL is the physiological ligand of Fas. FasL is expressed on the surface of activated cytotoxic T lymphocytes (CTL) (30) (31) (32) . We reasoned that if STAT1 mediates tumor cell sensitivity to Fas-mediated apoptosis in vivo (Fig. 4) , then the tumor-infiltrating CTLs (2) might be CAN-12-1347 the source of FasL that initiates tumor cell apoptosis in vivo. Next, we analyzed human STS specimens for CTL levels. Immunohistochemical staining of tumor specimens with CD8-specific mAb indicated that CTLs are present in 5 of the 5 specimens analyzed. The CTL infiltration level differs from specimens to specimens. However, CTLs are relatively evenly distributed inside the tumor tissues (Fig. 6A) 
uSTAT1 represses Jak1 expression to inhibit IFN-γ-induced STAT1 phosphorylation
Disruption of IRF8 function not only leads to up-regulation of uSTAT1 (Fig. 1) , but also inhibition of IFN-γ-induced STAT1 phosphorylation (Fig. 7A) . Analysis of pSTAT1 activity using EMSA indicated that pSTAT1 binding to GAS-containing DNA is also diminished in sarcoma cells overexpressing IRF8 mutants (Fig. 7B) . To determine whether diminished STAT1 phosphorylation is due to uSTAT1 up-regulation, we silenced uSTAT1 in CMS4 sarcoma cells and analyzed the expression level of Jak1. RT-PCR analysis revealed that silencing STAT1 in CMS4 cells resulted in up-regulation of Jak1 (Fig. 7C) . Our data thus suggest that uSTAT1 is a repressor of Jak1 expression.
Next, we analyzed pSTAT1 and uSTAT1 activation and expression kinetics in CMS4 cells after IFN-γ treatment. As reported in the literature in other types of cells (11), IFN-γ induced rapid STAT1 phosphorylation, however, pSTAT1 also disappeared rapidly ( 
7D). In contrast, uSTAT1 started to accumulate after pSTAT1 degradation and showed constant up-regulation for at least 2 days in CMS4 cells after IFN-γ treatment (Fig. 7D) .
Taken together, our data suggest that uSTAT1 is a repressor of Jak1 and functions as a feedback terminator of the IFN-γ/pSTAT1 signaling pathway.
Discussion
IFN-γ is a pleiotropic cytokine secreted by activated T cells and NK cells and plays a
critical role in the host cancer immunosurveillance (1, 33) . STAT1 is the key mediator of the IFN-γ signaling pathway and has been shown to function as a tumor suppressor (1, 2, 4). However, STAT1 hyperactivation and chronic IFN-γ signaling is observed to be linked to promotion of inflammation-mediated spontaneous cancer development (6), and
STAT1
-/-mice are partially protected from leukemia development (34) . Furthermore, overexpression of STAT1 is associated with tumor cell resistance to chemotherapeutic agents and radiation (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . These studies suggest that STAT1 might also function as a tumor promoter.
In this study, we observed two interesting phenomena in an experimental metastasis mouse sarcoma model in vivo: 1) a positive correlation between uSTAT1 expression level and metastatic potential of mouse sarcoma cells (Fig. 1A) ; and 2) an inverse correlation between IFN-γ-induced pSTAT1 level and metastatic potential of mouse sarcoma cells (Fig. 7A & B) . More interestingly, consistent with what was observed in the mouse sarcoma tumor model (Fig. 7A & B) and in human colorectal and squamous cell cancer patients (2, 3), we observed that human STS patients with high percentage of p/nSTAT1 + tumor cells show a trend of better disease-specific survival (Fig. 3A) , whereas STS patients with higher level of cSTAT1 protein in their tumor cells exhibit significantly worse disease-specific survival (Fig. 3B) . Our data thereby suggest that pSTAT1 functions as a tumor suppressor and uSTAT1 acts as a tumor promoter in sarcoma cells.
The mechanisms underlying STAT1 in tumor promotion are still elusive. The observation that overexpression of STAT1 is associated with resistance of tumor cells to chemotherapeutic agents and radiation suggest that STAT1 might confer tumor cell resistance to apoptosis to promote tumor development (35) (36) (37) (38) (40) (41) (42) (43) (44) (45) . Indeed, silencing STAT1 enhanced tumor cell sensitivity to apoptosis induction by chemotherapeutic agents and radiation (36, 43, 45) . In this study, we demonstrated that silencing STAT1 significantly increased sensitivity of sarcoma cells to FasL-induced apoptosis (Fig. 4) .
The Fas-FasL system plays a critical role in suppression of tumor development under physiological conditions (46-49). FasL is primarily expressed on activated CTLs (30-32).
In this study, we also observed CTL infiltration in human STS tissues (Fig. 6A) and that tumor-infiltrating CTLs express FasL in vivo (Fig. 6B) . These results thus suggest that uSTAT1 might confer sarcoma cell resistance to Fas-mediated apoptosis to escapes CTLmediated tumor suppression in vivo (Figs. 1-3 ). uSTAT1 is a transcription factor (50) and has been shown to directly regulate the expression of several genes with known functions in apoptosis regulation, including BclxL and STAT3 (25, 26) . We observed that uSTAT1 functions as a repressor of Bcl-xL in sarcoma cells (Fig. 5) . However, uSTAT1 also functions as a Bad suppressor (Fig. 5c) , and Bad forms a complex with Bcl-xL in sarcoma cells (Fig. 5D) . Therefore, uSTAT1-mediated suppression of Bcl-xL does not lead to increased sensitivity of the sarcoma cells to apoptosis induction. Silencing STAT1 resulted in up-regulation of Fas (Fig. 5B) suggesting that uSTAT1 is a Fas repressor, and therefore, uSTAT1 might use repressing Fas expression to confer sarcoma cell resistance to FasL-induced apoptosis.
Jak1 is the key kinase that phosphorylates the IFN-γR and subsequently STAT1. It has been shown that tumor cells use down-regulation of Jak1 to impair the IFN-γ signaling pathway. In this study, we observed that uSTAT1 also functions as a repressor of Jak1 to impair pSTAT1 formation (Fig. 7A & B) . Therefore, uSTAT1 not only represses expression of Fas and Bad to confer the tumor cell resistance to Fas-mediated apoptosis (Fig. 4 & 5) , but also represses Jak1 expression to potentially terminate STAT1 phosphorylation (Fig. 7) . Because IFN-γ/pSTAT1 can up-regulate Fas expression and enhances tumor cell sensitivity to apoptosis induction (39) p=0.03 
